Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

Leuk Lymphoma. 2020 Dec;61(14):3507-3510. doi: 10.1080/10428194.2020.1808210. Epub 2020 Aug 24.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dasatinib / therapeutic use
  • Humans
  • Philadelphia Chromosome
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Protein Kinase Inhibitors / adverse effects
  • Surgical Wound*

Substances

  • Protein Kinase Inhibitors
  • Dasatinib